 "Sun Pharma Advanced Research hits new high; zooms 200% in 2015")
Shares of Sun Pharma Research Company (SPARC) has zoomed 19% to Rs 562, extending its 15% rally past two trading days, after the company received approval from US Food and Drug Administration (USFDA) for antiepileptic drug.
The stock opened at Rs 477 and touched a record high of Rs 565 on BSE. The trading volumes on the counter nearly doubled with a combined 5.72 million shares changed hands on the counter till 0947 hours on BSE and NSE.
Meanwhile, thus far in 2015, the stock has outperformed the market by surging 200% from Rs 187 at the beginning of the current calendar year compared with 5.7% rise in the benchmark S&P BSE Sensex.
"The USFDA has approved its new drug application (NDA) for Elepsia XR (Levetiracetam extended-release tablets 1000 mg and 1500 mg)," says SPARC in its filing to the exchange.
Elepsia is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy.
"Levetiracetam is a very successful and highly effective antiepileptic drug, says Anil Raghavan, chief executive officer of SPARC.
The product will be manufactured by Sun Pharmaceutical Industries at its Halol (Gujarat) facility in India.
The stock opened at Rs 477 and touched a record high of Rs 565 on BSE. The trading volumes on the counter nearly doubled with a combined 5.72 million shares changed hands on the counter till 0947 hours on BSE and NSE.
Meanwhile, thus far in 2015, the stock has outperformed the market by surging 200% from Rs 187 at the beginning of the current calendar year compared with 5.7% rise in the benchmark S&P BSE Sensex.
"The USFDA has approved its new drug application (NDA) for Elepsia XR (Levetiracetam extended-release tablets 1000 mg and 1500 mg)," says SPARC in its filing to the exchange.
Elepsia is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy.
"Levetiracetam is a very successful and highly effective antiepileptic drug, says Anil Raghavan, chief executive officer of SPARC.
The product will be manufactured by Sun Pharmaceutical Industries at its Halol (Gujarat) facility in India.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%